ObjectiveGI

ObjectiveGI improves the prognosis of silent chronic diseases by bringing excellent clinical research to physicians and patients. Our initial focus is on the NASH market (affecting 200,000+ people), where our proprietary technology and processes drive innovation and accelerate time to market, as there are currently no FDA-approved treatments in this field.